Nouvelles molécules dans le cancer de la vessie.

C. Massard; B. Albouy; M. Gross-Goupil; A. Ravaud

Nouvelles molécules dans le cancer de la vessie.

C. Massard, B. Albouy, M. Gross-Goupil, A. Ravaud

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

1 Citation (Scopus)

Résumé

Cisplatin-based chemotherapy (MVAC : cisplatin, methotrexate, adriamycin, vinblastine ; or GC : cisplatin, gemcitabine) has been the standard of care for patients with advanced urothelial tumor during the last twenty years. Greater knowledge in the molecular biology of bladder cancer lead to the identification of promising target such as EGFR, HER2, or VEGF-VEGFR pathways. The role of targeted therapies as monotherapy, in combination with chemotheray or as maintenance post-chemotherapy is currently under study.

Titre traduit de la contribution	Bladder cancer and new drugs
langue originale	Français
Pages (de - à)	43-50
Nombre de pages	8
journal	Bulletin du Cancer
Volume	97 Suppl Cancer de la vessie
état	Publié - 1 janv. 2010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cb5f86a583ac421c9d5804cba189d099,

title = "Nouvelles mol{\'e}cules dans le cancer de la vessie.",

abstract = "Cisplatin-based chemotherapy (MVAC : cisplatin, methotrexate, adriamycin, vinblastine ; or GC : cisplatin, gemcitabine) has been the standard of care for patients with advanced urothelial tumor during the last twenty years. Greater knowledge in the molecular biology of bladder cancer lead to the identification of promising target such as EGFR, HER2, or VEGF-VEGFR pathways. The role of targeted therapies as monotherapy, in combination with chemotheray or as maintenance post-chemotherapy is currently under study.",

author = "C. Massard and B. Albouy and M. Gross-Goupil and A. Ravaud",

year = "2010",

month = jan,

day = "1",

language = "Fran{\c c}ais",

volume = "97 Suppl Cancer de la vessie",

pages = "43--50",

journal = "Bulletin du Cancer",

issn = "0007-4551",

}

TY - JOUR

T1 - Nouvelles molécules dans le cancer de la vessie.

AU - Massard, C.

AU - Albouy, B.

AU - Gross-Goupil, M.

AU - Ravaud, A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Cisplatin-based chemotherapy (MVAC : cisplatin, methotrexate, adriamycin, vinblastine ; or GC : cisplatin, gemcitabine) has been the standard of care for patients with advanced urothelial tumor during the last twenty years. Greater knowledge in the molecular biology of bladder cancer lead to the identification of promising target such as EGFR, HER2, or VEGF-VEGFR pathways. The role of targeted therapies as monotherapy, in combination with chemotheray or as maintenance post-chemotherapy is currently under study.

AB - Cisplatin-based chemotherapy (MVAC : cisplatin, methotrexate, adriamycin, vinblastine ; or GC : cisplatin, gemcitabine) has been the standard of care for patients with advanced urothelial tumor during the last twenty years. Greater knowledge in the molecular biology of bladder cancer lead to the identification of promising target such as EGFR, HER2, or VEGF-VEGFR pathways. The role of targeted therapies as monotherapy, in combination with chemotheray or as maintenance post-chemotherapy is currently under study.

UR - http://www.scopus.com/inward/record.url?scp=77953929106&partnerID=8YFLogxK

M3 - Article

C2 - 20534389

AN - SCOPUS:77953929106

SN - 0007-4551

VL - 97 Suppl Cancer de la vessie

SP - 43

EP - 50

JO - Bulletin du Cancer

JF - Bulletin du Cancer

ER -